Database release

This release contains 997 approved relationships.

View on GitHub

Added entries:

• (FDA) BCR::ABL1 and sensitivity to asciminib for patients with chronic myeloid leukemia in chronic phase.
• (FDA) BCR::ABL1 and ABL1 p.T315I and sensitivity to asciminib for patients with chronic myeloid leukemia in chronic phase.
• (FDA) PIK3CA variants and sensitivity to inavolisib for patients with HR+, HER2-negative, locally advanced or metastatic breast cancer.

Revised entries:

• (FDA) BCR::ABL1 and sensitivity to asciminib for patients with previously treated chronic myeloid leukemia in chronic phase was generalized to be for previously treatmented patients, instead of specifically for previously treated with two or more TKIs.